Show simple item record

dc.contributor.authorAhishali, Bülent
dc.contributor.authorkalaycı, RİVAZE
dc.contributor.authorElmas, I
dc.contributor.authorKudat, Hasan
dc.contributor.authorArican, Nadir
dc.contributor.authorBilgic, B
dc.contributor.authorKucuk, Mutlu
dc.contributor.authorUzun, Hafize
dc.contributor.authorKaya, Mehmet
dc.date.accessioned2021-03-04T12:22:09Z
dc.date.available2021-03-04T12:22:09Z
dc.date.issued2005
dc.identifier.citationkalaycı R., Kaya M., Elmas I., Arican N., Ahishali B., Uzun H., Bilgic B., Kucuk M., Kudat H., "Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats", BRAIN RESEARCH, cilt.1042, sa.2, ss.184-193, 2005
dc.identifier.issn0006-8993
dc.identifier.othervv_1032021
dc.identifier.otherav_76f5d529-d300-49bf-ab61-0a63e6f49085
dc.identifier.urihttp://hdl.handle.net/20.500.12627/81668
dc.identifier.urihttps://doi.org/10.1016/j.brainres.2005.02.044
dc.description.abstractRecent studies suggest that 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, can have direct effects on blood vessels beyond their cholesterol-lowering effects. We investigated the effects of atorvastatin on the functional and structural properties of blood-brain barrier (BBB) and the activity of astrocytes during the N-omega-nitro-L-arginine methyl ester (L-NAME) hypertension followed by angiotensin (ANG) II. We found that decreases in concentration of serum catalase and plasma nitric oxide (NO) induced by L-NAME were significantly ameliorated by atorvastatin, whereas L-NAME-induced serum malondialdehyde and cholesterol concentration increases were significantly reduced by atorvastatin. The content of Evans blue (EB) dye significantly increased in cerebellum, left cerebral cortex and diencephalon regions but atorvastatin markedly reduced the increased BBB permeability to EB in the brain regions of animals treated with L-NAME and L-NAME plus ANG II. Brain vessels of L-NAME-treated animals showed a considerable loss of immunoreactivity of tight junction proteins, zonula occludens (ZO)-1 and occludin. Immunoreactivity for ZO-1 and occludin increased in animals treated with atorvastatin and L-NAME plus atorvastatin. Glial fibrillary acidic protein (GFAP) immunoreactivity was seen in few astrocytes in the brain sections of L-NAME, but immunoreactivity for GFAP increased in L-NAME plus atorvastatin-treated animals. We suggest that long-term L-NAME treatment may affect BBB permeability through disruption of tight junction proteins, at least partly, via decreased NO concentration and increased oxidant capacity; the improvement of BBB integrity and astrocytic activity would be more closely associated with the action of atorvastatin favoring the increase in anti-oxidant capacity and expression of tight junction proteins and GFAP. (c) 2005 Elsevier B.V. All rights reserved.
dc.language.isoeng
dc.subjectSinirbilim ve Davranış
dc.subjectNEUROSCIENCES
dc.subjectTemel Bilimler
dc.subjectYaşam Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.titleEffects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats
dc.typeMakale
dc.relation.journalBRAIN RESEARCH
dc.contributor.department, ,
dc.identifier.volume1042
dc.identifier.issue2
dc.identifier.startpage184
dc.identifier.endpage193
dc.contributor.firstauthorID5557


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record